Latest News and Press Releases

Ítarlegri tilkynning á ensku sem veitir nánari upplýsingar um fjárhag og rekstur á fjórða ársfjórðungi 2025 og árinu í heild er birt á slóðinni: https://investors.alvotech.com/earnings-calendar. ...

REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines...

REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients...

REYKJAVÍK (4. Mars 2026) – Alvotech (NASDAQ: ALVO) mun birta uppgjör ársins 2025 og fjórða ársfjórðungs miðvikudaginn 18. Mars 2026, eftir lokun markaða í Bandaríkjunum. Fundur til kynningar á...

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf....

Í viðhengi eru tvær tilkynningar um viðskipti stjórnenda og tengdra aðila sem lagðar voru inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur...

REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

REYKJAVIK (11. febrúar 2026) - Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út tólf og hálfa milljón (12.500.000) nýrra almennra hluta í félaginu. Dótturfélag...

The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland,...

The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, ICELAND...